Download Free From Alchemy To Ipo Book in PDF and EPUB Free Download. You can read online From Alchemy To Ipo and write the review.

A fascinating glimpse inside the life-and-death business of biotechnology.
This comparative study looks at the early development of biotechnology in the US and Japan. Drawing on primary and secondary sources it traces the historical roots of recombinant DNA technology, discusses the tensions between regulation and promotional policies and identifies the major actors and strategies that launched biotechnology in both countries. Developing several strands of theory in economic history, science and technology policy, the book proposes a simple model that relates the differences in the two countries' responses to variations in the availability of institutional, financial and organizational resources needed to commercialize the new technology.
Biocapital is a major theoretical contribution to science studies and political economy. Grounding his analysis in a multi-sited ethnography of genomic research and drug development marketplaces in the United States and India, Kaushik Sunder Rajan argues that contemporary biotechnologies such as genomics can only be understood in relation to the economic markets within which they emerge. Sunder Rajan conducted fieldwork in biotechnology labs and in small start-up companies in the United States (mostly in the San Francisco Bay area) and India (mainly in New Delhi, Hyderabad, and Bombay) over a five-year period spanning 1999 to 2004. He draws on his research with scientists, entrepreneurs, venture capitalists, and policymakers to compare drug development in the two countries, examining the practices and goals of research, the financing mechanisms, the relevant government regulations, and the hype and marketing surrounding promising new technologies. In the process, he illuminates the global flow of ideas, information, capital, and people connected to biotech initiatives. Sunder Rajan’s ethnography informs his theoretically sophisticated inquiry into how the contemporary world is shaped by the marriage of biotechnology and market forces, by what he calls technoscientific capitalism. Bringing Marxian theories of value into conversation with Foucaultian notions of biopolitics, he traces how the life sciences came to be significant producers of both economic and epistemic value in the late twentieth century and early twenty-first.
Based on her research of 800 biotechnology companies and 3,200 biotechnology executives, Harvard Business School professor Monica Higgins discovered that one firm–Baxter–was the breeding ground for today’s most successful biotechnology ventures. This phenomena of one organization spawning an industry has also been seen in the high-tech (Hewlett-Packard) and semiconductor industries (Fairchild). However, until now there has been no suitable explanation of why and how these organizations were able to create the next generation of industry leaders. Career Imprints shows why Baxter was so successful in spawning senior executives and offers an understanding of what it takes for an organization to produce leaders that will dominate an industry for years to come. In this important book, Higgins shows that an organization’s "career imprint"¾the result of company systems, structure, strategy, and culture¾that employees take with them throughout their careers is the key to creating great leaders. By understanding these factors, staff, human resource executives, and CEOs can analyze their own organization’s career imprint and develop leaders.
The book is about the link between science and business - how discoveries made in academic laboratories are taken up by venture capitalists and investors, and converted into products which, if they are successful, provide treatments for disease and may generate substantial returns for investors.
"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
Supported with 119 illustrations, this milestone work discusses key optical imaging techniques in self-contained chapters; describes the integration of optical imaging techniques with other modalities like MRI, X-ray imaging, and PET imaging; provides a software platform for multimodal integration; presents cutting-edge computational and data processing techniques that ensure rapid, cost-effective, and precise quantification and characterization of the clinical data; covers advances in photodynamic therapy and molecular imaging, and reviews key clinical studies in optical imaging along with regulatory and business issues.
Examining the role of the much-vaunted concepts of regional clusters in the prosperity and economic expansion of countries, this work looks at the different experiences of industrial districts and high-tech regions such as Silicon Valley, Boston's biotech region, and Hsinchu-Taipei.
This title examines the history of biotechnology when it was new, especially when synonymous with recombinant DNA technology. It focuses on the academic community in the San Francisco Bay Area where recombinant DNA technology was developed and adopted as the first major commercial technology for genetic engineering at Stanford in the 1970s. The book argues that biotechnology was initially a hybrid creation of academic and commercial institutions held together by the assumption of a positive relationship between private ownership and the public interest.
For decades, government, industry, and the mainstream media have extolled the virtues of biotechnology while downplaying its negative side effects. Focusing on agriculture, Resistance Is Fertile challenges this dominant rhetoric by analyzing the major issues around which opponents of biotechnology in Canada are mobilizing resistance – namely, the enclosure of the biological and the knowledge commons, which together form the BioCommons. What emerges is an empirically and theoretically informed analysis of Canada’s regulatory regime, the corporate control of seeds, and attempts to construct and control public discussions about agricultural biotechnology.